The federal subsidy that softened standalone Medicare Part D premiums for two straight years will not return for 2027, and the government’s own estimates point to sharply higher costs for a large share of drug-plan members. Federal officials are winding down a Part D premium stabilization program at the end of 2026, returning the standalone drug market to standard pricing. Under those projections, roughly 45 percent of members in standalone drug plans could see monthly premiums rise by more than $10 next year. Those figures are estimates rather than final plan prices, which do not post until September.
The subsidy that ends after 2026
The program at the center of the change is the Part D Premium Stabilization Demonstration, a voluntary arrangement that paid standalone prescription drug plans to hold premium swings within a set band. It was created to blunt the volatility that followed the redesign of the Part D benefit under the 2022 drug law, which capped what members pay out of pocket but shifted more cost onto plans. For two years the subsidy absorbed part of that pressure, keeping advertised premiums lower than they otherwise would have been.
Federal officials announced they would let the demonstration conclude at the end of the 2026 plan year, saying insurers now have enough experience with the redesigned benefit to price their bids without the extra support. In the same announcement, the agency set the 2027 national average monthly bid and the base beneficiary premium that anchors the program, a technical step confirming that the subsidy’s removal is built into next year’s numbers, according to a federal fact sheet on the 2027 bid amounts. The change is a decision already made, not a proposal still pending.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. Our free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
How high the increases could go
The change lands hardest on members of standalone prescription drug plans, the coverage that people who stay with Original Medicare buy separately to fill the drug gap. Medicare Advantage plans that bundle drug coverage draw on other funding and are affected differently, so the sharpest premium pressure falls on the standalone market that older beneficiaries on traditional Medicare rely on. Removing the subsidy does not raise every premium, and it does not raise them evenly.
By the agency’s breakdown, about a quarter of standalone drug-plan members are projected to see premiums hold steady or fall from 2026 to 2027, and roughly another 30 percent are expected to face increases of less than $10 a month. The remaining group, close to 45 percent of members, is projected to see monthly premiums climb by more than $10, with many of those increases landing in the $11-to-$20 range, according to an early analysis of the 2027 enrollment period. Spread across a year, a $15 monthly increase adds $180 to a member’s drug-plan cost before any change in deductibles or copays.
These numbers remain projections rather than settled prices. They describe the expected pattern once the subsidy is gone, not the specific premium any single plan will charge. The actual figures depend on each insurer’s final bid and on which plan a member holds, and they are not locked in until the government publishes plan-level details in the fall. A member in one plan could see no change while a neighbor in another absorbs the full increase.
Comparing plans before the December deadline
Plan-specific premiums and drug lists for 2027 are released in September, ahead of the annual window when members can change coverage. From October 15 through December 7, beneficiaries can switch drug plans or Medicare Advantage plans for coverage that begins January 1, using Medicare’s plan comparison tool to price their own prescriptions against each option. The preview gives shoppers a few weeks to study the numbers before the switching window opens.
The cost of inattention is real because a drug plan renews automatically. A member who does nothing keeps the same plan into 2027 at whatever new premium the insurer sets, even if a competing plan covers the same medications for less. With the stabilization subsidy gone, the gap between the cheapest suitable plan and a member’s current one is likely to widen, which makes an active comparison more valuable than in years when premiums barely moved.
One protection is not going away. The annual limit on what a member pays out of pocket for covered drugs, introduced under the same 2022 law, remains in place for 2027, so the change reshapes premiums rather than the ceiling on a year’s medication costs. That distinction matters for anyone tempted to drop coverage over a higher premium, because a plan with a modestly larger monthly cost can still cap catastrophic drug spending in a way that going without a plan does not.
What the subsidy’s expiration changes is not the structure of Part D but the price of standing still. For two years the program masked part of the cost of the redesigned benefit; without it, more of that cost surfaces on the premium line, and it surfaces unevenly. Whether a given retiree feels the full increase or escapes it will depend less on the headline projection than on whether they open the September notices and compare plans before the December deadline closes.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
More Financial Reading
